Nicole Lamanna

Dr. Nicole Lamanna serves as the Judy Horrigan Professor of Medicine and Director of the Chronic Lymphocytic Leukemia (CLL) Program on the Leukemia Service for the Hematologic Malignancies Section in the Hematology/Oncology Division at Columbia University Medical Center. Dr. Lamanna specializes in the treatment of adult patients with acute and chronic leukemias with a focus on chronic lymphocytic leukemia (CLL). Her clinical research focus has been the development of novel combination therapies that include immune-modulatory drugs, kinase inhibitors, bcl-2 inhibitors, monoclonal antibodies as well new agents in development for this disease. She is a staunch patient advocate and participates regularly in CLL patient advocacy groups with the goal of educating patients about their disease and treatment options. She has lectured and chaired CLL sessions at international and national meetings and has published in various scientific journals, including Blood, Journal of Clinical Oncology, Lancet and The New England Journal of Medicine.

Richard R. Furman, MD attended medical school at the Mount Sinai School of Medicine followed by Internal Medicine Residency at the Hospital of the University of Pennsylvania. He subsequently completed fellowship in Hematology and Oncology at Weill Cornell Medical College. After fellowship, Dr. Furman performed laboratory based research on cognate and non-cognate immune interactions in CLL, focusing on NF-kappaB and B cell differentiation. Dr. Furman subsequently left the laboratory to pursue clinical research and patient care with an interest on the development of non-chemotherapeutic approaches for the treatment of CLL and lymphomas. He initially focused on thalidomide and lenalidomide, before working on novel monoclonal antibodies, BCR antagonists, and other small molecule inhibitors. Dr. Furman has played a key role in the development of idelalisib, ibrutinib, acalabrutinib, and venetoclax, as well as understanding and treating mechansims of resistance. Dr. Furman is currently the Director of the CLL Research Center and the Chair of the Lymphoma Program at Weill Cornell Medicine.

Dr. Nicole Lamanna serves as the Judy Horrigan Professor of Medicine and Director of the Chronic Lymphocytic Leukemia (CLL) Program on the Leukemia Service for the Hematologic Malignancies Section in the Hematology/Oncology Division at Columbia University Medical Center. Dr. Lamanna specializes in the treatment of adult patients with acute and chronic leukemias with a focus on chronic lymphocytic leukemia (CLL). Her clinical research focus has been the development of novel combination therapies that include immune-modulatory drugs, kinase inhibitors, bcl-2 inhibitors, monoclonal antibodies as well new agents in development for this disease. She is a staunch patient advocate and participates regularly in CLL patient advocacy groups with the goal of educating patients about their disease and treatment options. She has lectured and chaired CLL sessions at international and national meetings and has published in various scientific journals, including Blood, Journal of Clinical Oncology, Lancet and The New England Journal of Medicine.